Asset profile
DD01
Peptide
Evidence outlook · lead readout
NCT06410924 · NAFLD, NASH
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06410924: The study randomized 67 participants to DD01 or placebo and masked participants, investigators, and outcome assessors. Its primary endpoint was a surrogate measure—the proportion achieving at least a 30% reduction in liver fat by MRI-PDFF—and results have not been posted, so whether the primary endpoint was met is unknown.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.